[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100510911":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":28,"centralContacts":35,"locations":41,"responsibleParty":132,"collaborators":134,"id":139,"slug":140,"hasResults":141,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":10,"eligibilityCriteria":145,"healthyVolunteers":146,"sex":147,"minAge":148,"maxAge":149,"enrollmentInfo":150,"targetDuration":10,"studyType":153,"phases":10,"briefSummary":154,"conditions":155,"keywords":159,"overallStatus":44,"whyStopped":10,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":173},{"fullName":5,"class":6},"Children's Hospital of Philadelphia","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"RTT Females",null,"Females with Rett Syndrome",[13,14],"Other: EEG and Auditory and Visual Evoked Potentials (AEP and VEP)","Other: Clinical assessment",{"label":16,"type":10,"description":17,"interventionNames":18},"Controls","Females with typical development",[13],[20,24],{"type":6,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"EEG and Auditory and Visual Evoked Potentials (AEP and VEP)","Through up to eight standardized sessions, participants will undergo AEP and VEP, as well as resting state EEG.",[16,9],{"type":6,"name":25,"description":26,"armGroupLabels":27,"otherNames":10},"Clinical assessment","Established clinical measures for RTT will be collected for RTT participants",[9],[29,32],{"name":30,"affiliation":5,"role":31},"Eric Marsh, MD, PhD","PRINCIPAL_INVESTIGATOR",{"name":33,"affiliation":34,"role":31},"Jeffrey Neul, MD, PhD","Vanderbilt University Medical Cener",[36],{"name":37,"role":38,"phone":39,"phoneExt":10,"email":40},"Holly Dubbs, MS. CGC","CONTACT","215-590-1719","dubbsh@chop.edu",[42,62,75,90,103,119],{"facility":43,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Children's Hospital of Los Angeles","RECRUITING","Los Angeles","California","90027","United States","US",{"type":51,"coordinates":52},"Point",[53,54],-118.24368,34.05223,{"lat":54,"lon":53},[57,59],{"name":58,"role":31,"phone":10,"phoneExt":10,"email":10},"Shefali Spurling Jeste, MD",{"name":60,"role":61,"phone":10,"phoneExt":10,"email":10},"Payal Kenia Gu, MD","SUB_INVESTIGATOR",{"facility":63,"status":44,"city":64,"state":65,"zip":66,"country":48,"countryCode":49,"cosmosGeoPoint":67,"geoPoint":71,"contacts":72},"Children's Hospital Colorado","Aurora","Colorado","80045",{"type":51,"coordinates":68},[69,70],-104.83192,39.72943,{"lat":70,"lon":69},[73],{"name":74,"role":31,"phone":10,"phoneExt":10,"email":10},"Timothy Benke, MD, PhD",{"facility":76,"status":44,"city":77,"state":78,"zip":79,"country":48,"countryCode":49,"cosmosGeoPoint":80,"geoPoint":84,"contacts":85},"Boston Children's Hospital","Brookline","Massachusetts","02445",{"type":51,"coordinates":81},[82,83],-71.12116,42.33176,{"lat":83,"lon":82},[86,88],{"name":87,"role":31,"phone":10,"phoneExt":10,"email":10},"April Levin, MD",{"name":89,"role":61,"phone":10,"phoneExt":10,"email":10},"David Lieberman, MD, PhD",{"facility":5,"status":44,"city":91,"state":92,"zip":93,"country":48,"countryCode":49,"cosmosGeoPoint":94,"geoPoint":98,"contacts":99},"Philadelphia","Pennsylvania","19104",{"type":51,"coordinates":95},[96,97],-75.16362,39.95238,{"lat":97,"lon":96},[100,102],{"name":101,"role":38,"phone":39,"phoneExt":10,"email":40},"Holly Dubbs, MS, CGC",{"name":30,"role":31,"phone":10,"phoneExt":10,"email":10},{"facility":104,"status":44,"city":105,"state":106,"zip":107,"country":48,"countryCode":49,"cosmosGeoPoint":108,"geoPoint":112,"contacts":113},"Vanderbilt University Medical Center","Nashville","Tennessee","37232",{"type":51,"coordinates":109},[110,111],-86.78444,36.16589,{"lat":111,"lon":110},[114,118],{"name":115,"role":38,"phone":116,"phoneExt":10,"email":117},"Nicole Thompson","615-343-4586","Nicole.i.thompson@vumc.org",{"name":33,"role":31,"phone":10,"phoneExt":10,"email":10},{"facility":120,"status":44,"city":121,"state":122,"zip":123,"country":48,"countryCode":49,"cosmosGeoPoint":124,"geoPoint":128,"contacts":129},"Texas Children's Hospital","Houston","Texas","77030",{"type":51,"coordinates":125},[126,127],-95.36327,29.76328,{"lat":127,"lon":126},[130],{"name":131,"role":31,"phone":10,"phoneExt":10,"email":10},"Bernhard Suter, MD",{"type":133,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[135,138],{"name":136,"class":137},"National Institute of Neurological Disorders and Stroke (NINDS)","NIH",{"name":104,"class":6},"100510911","neurophysiologic-biomarkers-in-rett-syndrome-100510911",false,"NCT05932589","Neurophysiologic Biomarkers in Rett Syndrome","Characterization of Translatable Neurophysiological Biomarkers to Enhance Therapeutic Development in Rett Syndrome","Inclusion Criteria:\n\n1. Rett Group: Females ages 3-18 (inclusive) with a clinical diagnosis of RTT with a likely pathogenic or known pathogenic variant in MECP2.\n2. Likely Rett Group: Females from 1 year to \\\u003C 5 years of age with MECP2 variant if regression has not yet occurred or child is within 6 months of last skill loss.\n3. Typically developing (TD) Group: Females age matched to RTT population (1-18) with no developmental or cognitive concerns as assessed using the Child\u002FAdult Behavioral Checklist, Survey of Well-Being of Young Children (\\\u003C5yo), or the Wide Range Achievement Test-4 (\\>5 yo).\n\nExclusion Criteria:\n\nRett and Likely Rett Groups:\n\n1. Presence of a duplication in MECP2 or any other identified pathogenic mutation in another gene.\n2. Active medical conditions not typically found in RTT.\n\nTypically Developing Group:\n\n1. Score below norms on the performance tests\n2. Have a known neurological disorder (excluding migraine)\n3. Being on neuroactive medications.",true,"FEMALE","1 Year","18 Years",{"count":151,"type":152},202,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to identify candidate biomarkers in individuals with Rett Syndrome (RTT). The main questions it aims to answer are:\n\n* Do these biomarkers change during clinical changes in individuals with RTT?\n* Are biomarkers stable over time in clinically stable individuals?\n* Do these biomarkers correlate with severity of RTT?\n\nParticipants will be asked to undergo an electroencephalogram (EEG) with measurements of Evoked Potentials (EP) to measure electrical activity in the brain.\n\nResearchers will compare findings in individuals with RTT to those in typically developing individuals to see if there are differences between the two groups.",[156,157,158],"Rett Syndrome","RTT","Rett Syndrome, Atypical",[160,161,162,163],"Biomarker","EEG","Evoked Potentials","MECP2","2025-10-17",{"date":166,"type":167},"2025-10-20","ACTUAL",{"date":169,"type":167},"2023-10-11",{"date":171,"type":152},"2029-03-31",{"name":5,"class":6},6]